ResearcherWashington University in St. LouisNo recent work listed
Yassar M. Hashim
Matched on ORCID iD 0000-0002-4027-5768; OpenAlex author ID A5109954643. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 28
2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper
Papers 4
- The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. Co-author DOI 10.1186/s13046-016-0470-4↗
- Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. First author DOI 10.18632/oncotarget.9551↗
- Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. Co-author DOI 10.1016/j.molonc.2014.03.005↗
- Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- William G. Hawkins · 4 shared papers, 2014–2017 · strength 0.19
- Paper The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. DOI 10.1186/s13046-016-0470-4↗
- Paper Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic canc… DOI 10.18632/oncotarget.9551↗
- Paper Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. DOI 10.1016/j.molonc.2014.03.005↗
- Dirk M. Spitzer · 3 shared papers, 2014–2017 · strength 0.16
- Paper The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. DOI 10.1186/s13046-016-0470-4↗
- Paper Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic canc… DOI 10.18632/oncotarget.9551↗
- Paper Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. DOI 10.1016/j.molonc.2014.03.005↗
- Timothy M. Nywening · 1 shared paper, 2016 · strength 0.05
- Kerri A. Ohman · 1 shared paper, 2016 · strength 0.05
- David Arthur Tuveson · 1 shared paper, 2016 · strength 0.05
- Hervé Tiriac · 1 shared paper, 2016 · strength 0.05
- David G DeNardo · 1 shared paper, 2016 · strength 0.05
- John R. Hornick · 1 shared paper, 2014 · strength 0.04
- Peter S. Goedegebuure · 1 shared paper, 2014 · strength 0.04
- Neha L. Lad · 1 shared paper, 2014 · strength 0.03
- Jeffrey M. Sutton MD · 1 shared paper, 2014 · strength 0.03
- David A. Kooby · 1 shared paper, 2014 · strength 0.03
- Volkan N. Adsay · 1 shared paper, 2014 · strength 0.03
- Juan Manuel Sarmiento · 1 shared paper, 2014 · strength 0.03
- Alexander A. Parikh · 1 shared paper, 2014 · strength 0.03
- Daniel Erik Abbott · 1 shared paper, 2014 · strength 0.03
- Syed Ameen Ahmad · 1 shared paper, 2014 · strength 0.03
- Sharon Marie Weber · 1 shared paper, 2014 · strength 0.03
- Clifford S. Cho · 1 shared paper, 2014 · strength 0.03
- Emily R. Winslow · 1 shared paper, 2014 · strength 0.03
- David J. Bentrem · 1 shared paper, 2014 · strength 0.03
- Jen Jen Yeh · 1 shared paper, 2014 · strength 0.03
- Nipun B. Merchant · 1 shared paper, 2014 · strength 0.03
- Ryan C Fields · 1 shared paper, 2014 · strength 0.03
- Charles Raben Scoggins · 1 shared paper, 2014 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.